|  |  |  | Advertisement |  | Why Blood Cancer Journal is the journal for your research
*Fully open access: maximum visibility worldwide *Editorial: Peer reviewed by key editorial team and quick turnaround *Impact: now indexed by Thomson Reuters ISI for Impact Factor
For the full Guide to Authors click here. |
|  | | How To Manage… | Top |  | How to manage high-risk acute myeloid leukemiaE H Estey Leukemia 2012 26: 861-869; advance online publication, November 25, 2011; 10.1038/leu.2011.317 Abstract | Full Text |  |  |  | How to manage polycythemia veraF Passamonti Leukemia 2012 26: 870-874; advance online publication, December 9, 2011; 10.1038/leu.2011.334 Abstract | Full Text |  |  |  | How to manage essential thrombocythemiaG Finazzi Leukemia 2012 26: 875-882; advance online publication, November 4, 2011; 10.1038/leu.2011.306 Abstract | Full Text |  | Original Articles | Top |  | MOLECULAR TARGETS FOR THERAPY
| Role of stromal microenvironment in nonpharmacological resistance of CML to imatinib through Lyn/CXCR4 interactions in lipid raftsY Tabe, L Jin, K Iwabuchi, R-Y Wang, N Ichikawa, T Miida, J Cortes, M Andreeff and M Konopleva Leukemia 2012 26: 883-892; advance online publication, October 18, 2011; 10.1038/leu.2011.291 Abstract | Full Text |  |  |  | ACUTE LEUKEMIAS
| Safety, efficacy and biological predictors of response to sequential azacitidine and lenalidomide for elderly patients with acute myeloid leukemiaD A Pollyea, H E Kohrt, L Gallegos, M E Figueroa, O Abdel-Wahab, B Zhang, S Bhattacharya, J Zehnder, M Liedtke, J R Gotlib, S Coutre, C Berube, A Melnick, R Levine, B S Mitchell and B C Medeiros Leukemia 2012 26: 893-901; advance online publication, October 28, 2011; 10.1038/leu.2011.294 Abstract | Full Text |  |  |  | Identification of germline susceptibility loci in ETV6-RUNX1-rearranged childhood acute lymphoblastic leukemiaE Ellinghaus, M Stanulla, G Richter, D Ellinghaus, G te Kronnie, G Cario, G Cazzaniga, M Horstmann, R Panzer Grümayer, H Cavé, J Trka, O Cinek, A Teigler-Schlegel, A ElSharawy, R Häsler, A Nebel, B Meissner, T Bartram, F Lescai, C Franceschi, M Giordan, P Nürnberg, B Heinzow, M Zimmermann, S Schreiber, M Schrappe and A Franke Leukemia 2012 26: 902-909; advance online publication, November 11, 2011; 10.1038/leu.2011.302 Abstract | Full Text |  |  |  | Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemiaE McCormack, I Haaland, G Venås, R B Forthun, S Huseby, G Gausdal, S Knappskog, D R Micklem, J B Lorens, Ø Bruserud and B T Gjertsen Leukemia 2012 26: 910-917; advance online publication, November 8, 2011; 10.1038/leu.2011.315 Abstract | Full Text |  |  |  | The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis–relapse samples of precursor B-cell acute lymphoblastic leukemiaC E de Bock, A Ardjmand, T J Molloy, S M Bone, D Johnstone, D M Campbell, K L Shipman, T M Yeadon, J Holst, M D Spanevello, G Nelmes, D R Catchpoole, L F Lincz, A W Boyd, G F Burns and R F Thorne Leukemia 2012 26: 918-926; advance online publication, November 25, 2011; 10.1038/leu.2011.319 Abstract | Full Text |  |  |  | Silencing of ETV6/RUNX1 abrogates PI3K/AKT/mTOR signaling and impairs reconstitution of leukemia in xenograftsG Fuka, H-P Kantner, R Grausenburger, A Inthal, E Bauer, G Krapf, U Kaindl, M Kauer, M N Dworzak, D Stoiber, O A Haas and R Panzer-Grümayer Leukemia 2012 26: 927-933; advance online publication, November 18, 2011; 10.1038/leu.2011.322 Abstract | Full Text |  |  |  | Landscape of TET2 mutations in acute myeloid leukemiaS Weissmann, T Alpermann, V Grossmann, A Kowarsch, N Nadarajah, C Eder, F Dicker, A Fasan, C Haferlach, T Haferlach, W Kern, S Schnittger and A Kohlmann Leukemia 2012 26: 934-942; advance online publication, November 25, 2011; 10.1038/leu.2011.326 Abstract | Full Text |  |  |  | MYELODYSPLASIAS
| Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatmentM Y Follo, D Russo, C Finelli, S Mongiorgi, C Clissa, C Filì, C Colombi, M Gobbi, L Manzoli, M Piazzi, A M Martelli and L Cocco Leukemia 2012 26: 943-950; advance online publication, October 28, 2011; 10.1038/leu.2011.300 Abstract | Full Text |  |  |  | CHRONIC MYELOPROLIFERATIVE NEOPLASIAS
| An immature immunophenotype of bone marrow mast cells predicts for multilineage D816V KIT mutation in systemic mastocytosisC Teodosio, A C García-Montero, M Jara-Acevedo, I Álvarez-Twose, L Sánchez-Muñoz, J Almeida, J M Morgado, A Matito, L Escribano and A Orfao Leukemia 2012 26: 951-958; advance online publication, November 4, 2011; 10.1038/leu.2011.293 Abstract | Full Text |  |  |  | Nilotinib is effective in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blastic phaseF J Giles, H M Kantarjian, P D le Coutre, M Baccarani, F-X Mahon, R E Blakesley, N J Gallagher, K Gillis, S L Goldberg, R A Larson, A Hochhaus and O G Ottmann Leukemia 2012 26: 959-962; advance online publication, December 13, 2011; 10.1038/leu.2011.355 Abstract | Full Text |  |  |  | CHRONIC LYMPHOCYTIC LEUKEMIA
| Loss-of-function mutations within the IL-2 inducible kinase ITK in patients with EBV-associated lymphoproliferative diseasesR M Linka, S L Risse, K Bienemann, M Werner, Y Linka, F Krux, C Synaeve, R Deenen, S Ginzel, R Dvorsky, M Gombert, A Halenius, R Hartig, M Helminen, A Fischer, P Stepensky, K Vettenranta, K Köhrer, M R Ahmadian, H-J Laws, B Fleckenstein, H Jumaa, S Latour, B Schraven and A Borkhardt Leukemia 2012 26: 963-971; advance online publication, January 6, 2012; 10.1038/leu.2011.371 Abstract | Full Text |  |  |  | Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden ConsortiumW Wiktor-Jedrzejczak, C Dearden, L de Wreede, A van Biezen, L Brinch, V Leblond, M Brune, L Volin, M Kazmi, A Nagler, J Schetelig, T de Witte and P Dreger on behalf of the EBMT Chronic Leukemia Working Party Leukemia 2012 26: 972-976; advance online publication, November 25, 2011; 10.1038/leu.2011.304 Abstract | Full Text |  |  |  | STEM CELLS
| Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinibJ J W M Janssen, W Deenik, K G M Smolders, B J van Kuijk, W Pouwels, A Kelder, J J Cornelissen, G J Schuurhuis and G J Ossenkoppele Leukemia 2012 26: 977-984; advance online publication, December 9, 2011; 10.1038/leu.2011.347 Abstract | Full Text |  |  |  | MINIMAL RESIDUAL DISEASE
| Inhibition of CXCR4 in CML cells disrupts their interaction with the bone marrow microenvironment and sensitizes them to nilotinibE Weisberg, A K Azab, P W Manley, A L Kung, A L Christie, R Bronson, I M Ghobrial and J D Griffin Leukemia 2012 26: 985-990; advance online publication, December 20, 2011; 10.1038/leu.2011.360 Abstract | Full Text |  |  |  | IMMUNOLOGY
| Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL)C Buechele, T Baessler, S Wirths, J U Schmohl, B J Schmiedel and H R Salih Leukemia 2012 26: 991-1000; advance online publication, November 8, 2011; 10.1038/leu.2011.313 Abstract | Full Text |  |  |  | SENSITIVITY AND RESISTANCE TO THERAPY
| IGFBP7 participates in the reciprocal interaction between acute lymphoblastic leukemia and BM stromal cells and in leukemia resistance to asparaginaseA B A Laranjeira, J F de Vasconcellos, L Sodek, M C Spago, M C Fornazim, L G Tone, S R Brandalise, A E Nowill and J A Yunes Leukemia 2012 26: 1001-1011; advance online publication, October 18, 2011; 10.1038/leu.2011.289 Abstract | Full Text |  |  |  | ONCOGENES, FUSION GENES AND TUMOR SUPPRESSOR GENES
| CALM/AF10-positive leukemias show upregulation of genes involved in chromatin assembly and DNA repair processes and of genes adjacent to the breakpoint at 10p12M A Mulaw, A J Krause, A J Deshpande, L F Krause, A Rouhi, R La Starza, A Borkhardt, C Buske, C Mecucci, W-D Ludwig, C Lottaz and S K Bohlander Leukemia 2012 26: 1012-1019; advance online publication, November 8, 2011; 10.1038/leu.2011.307 Abstract | Full Text |  |  |  | APOPTOSIS
| RIP1 is required for IAP inhibitor-mediated sensitization of childhood acute leukemia cells to chemotherapy-induced apoptosisS Löder, M Fakler, H Schoeneberger, S Cristofanon, J Leibacher, N Vanlangenakker, M J M Bertrand, P Vandenabeele, I Jeremias, K-M Debatin and S Fulda Leukemia 2012 26: 1020-1029; advance online publication, December 16, 2011; 10.1038/leu.2011.353 Abstract | Full Text |  |  |  | ANIMAL MODELS
| Leukemic spleen cells are more potent than bone marrow-derived cells in a transgenic mouse model of CMLM Schemionek, T Spieker, L Kerstiens, C Elling, M Essers, A Trumpp, W E Berdel, C Müller-Tidow and S Koschmieder Leukemia 2012 26: 1030-1037; advance online publication, December 23, 2011; 10.1038/leu.2011.366 Abstract | Full Text |  |  |  | Aberrant expression of RasGRP1 cooperates with gain-of-function NOTCH1 mutations in T-cell leukemogenesisT Oki, J Kitaura, N Watanabe-Okochi, K Nishimura, A Maehara, T Uchida, Y Komeno, F Nakahara, Y Harada, T Sonoki, H Harada and T Kitamura Leukemia 2012 26: 1038-1045; advance online publication, November 25, 2011; 10.1038/leu.2011.328 Abstract | Full Text |  |  |  | LYMPHOMA
| Denileukin diftitox in combination with rituximab for previously untreated follicular B-cell non-Hodgkin's lymphomaS M Ansell, H Tang, P J Kurtin, P A Koenig, G S Nowakowski, D A Nikcevich, G D Nelson, Z Yang, D M Grote, S C Ziesmer, P T Silberstein, C Erlichman and T E Witzig Leukemia 2012 26: 1046-1052; advance online publication, October 21, 2011; 10.1038/leu.2011.297 Abstract | Full Text |  |  |  | Characterization of intratumoral follicular helper T cells in follicular lymphoma: role in the survival of malignant B cellsP Amé-Thomas, J Le Priol, H Yssel, G Caron, C Pangault, R Jean, N Martin, T Marafioti, P Gaulard, T Lamy, T Fest, G Semana and K Tarte Leukemia 2012 26: 1053-1063; advance online publication, October 21, 2011; 10.1038/leu.2011.301 Abstract | Full Text |  |  |  | The miRNA-17~92 cluster mediates chemoresistance and enhances tumor growth in mantle cell lymphoma via PI3K/AKT pathway activationE Rao, C Jiang, M Ji, X Huang, J Iqbal, G Lenz, G Wright, L M Staudt, Y Zhao, T W McKeithan, W C Chan and K Fu Leukemia 2012 26: 1064-1072; advance online publication, November 25, 2011; 10.1038/leu.2011.305 Abstract | Full Text |  |  |  | MYELOMA
| Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYCT Holien, T K Våtsveen, H Hella, C Rampa, G Brede, L A G Grøseth, M Rekvig, M Børset, T Standal, A Waage and A Sundan Leukemia 2012 26: 1073-1080; advance online publication, September 23, 2011; 10.1038/leu.2011.263 Abstract | Full Text |  |  |  | Syndecan-1 promotes the angiogenic phenotype of multiple myeloma endothelial cellsS Lamorte, S Ferrero, S Aschero, L Monitillo, B Bussolati, P Omedè, M Ladetto and G Camussi Leukemia 2012 26: 1081-1090; advance online publication, October 25, 2011; 10.1038/leu.2011.290 Abstract | Full Text |  |  |  | Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant ResearchA Mahindra, M E Kalaycio, J Vela-Ojeda, D H Vesole, M-J Zhang, P Li, J R Berenson, J M Bird, A Dispenzieri, J L Gajewski, R P Gale, L Holmberg, S Kumar, R A Kyle, H M Lazarus, S Lonial, J Mikhael, G A Milone, R Munker, R Nath, S Saccaro, L Bik To, D T Vogl, B Wirk and P Hari Leukemia 2012 26: 1091-1097; advance online publication, November 1, 2011; 10.1038/leu.2011.312 Abstract | Full Text |  |  |  | CD29 expressed on plasma cells is activated by divalent cations and soluble CD106 contained in the bone marrow plasma: refractory activation is associated with enhanced proliferation and exit of clonal plasma cells to circulation in multiple myeloma patientsE Martínez-Viñambres, J A García-Trujillo, E Rodríguez-Martín, L M Villar, J Coll and E Roldán Leukemia 2012 26: 1098-1105; advance online publication, December 2, 2011; 10.1038/leu.2011.335 Abstract | Full Text |  | Letters to the Editor | Top |  | DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemiaK H Metzeler, A Walker, S Geyer, R Garzon, R B Klisovic, C D Bloomfield, W Blum and G Marcucci Leukemia 2012 26: 1106-1107; advance online publication, November 29, 2011; 10.1038/leu.2011.342 Full Text |  |  |  | Characteristics of chronic lymphocytic leukemia with somatically acquired mutations in NOTCH1 exon 34K Shedden, Y Li, P Ouillette and S N Malek Leukemia 2012 26: 1108-1110; advance online publication, December 20, 2011; 10.1038/leu.2011.361 Full Text |  |  |  | NPM-MLF1 synergizes with Npm haploinsufficiency to enhance myeloid progenitor activityW-H Lee, S Salek-Ardakani, P P Pandolfi, H J M Brady, J de Boer and O Williams Leukemia 2012 26: 1110-1112; advance online publication, December 23, 2011; 10.1038/leu.2011.365 Full Text |  |  |  | Stromal cells and CD40 ligand (CD154) alter the miRNome and induce miRNA clusters including, miR-125b/miR-99a/let-7c and miR-17-92 in chronic lymphocytic leukaemiaS Willimott and S D Wagner Leukemia 2012 26: 1113-1116; advance online publication, October 25, 2011; 10.1038/leu.2011.299 Full Text |  |  |  | β-catenin is dynamically stored and cleared in multiple myeloma by the proteasome–aggresome–autophagosome–lysosome pathwayK Sukhdeo, M Mani, T Hideshima, K Takada, V Pena-Cruz, G Mendez, S Ito, K C Anderson and D R Carrasco Leukemia 2012 26: 1116-1119; advance online publication, November 4, 2011; 10.1038/leu.2011.303 Full Text |  |  |  | Majority of patients receiving initial therapy with lenalidomide-based regimens can be successfully mobilized with appropriate mobilization strategiesS Sinha, M A Gertz, M Q Lacy, A Dispenzieri, S R Hayman, F K Buadi, D Dingli, I N Micallef, W J Hogan, D A Gastineau, S V Rajkumar and S K Kumar Leukemia 2012 26: 1119-1122; advance online publication, October 28, 2011; 10.1038/leu.2011.308 Full Text |  |  |  | Specific deletion of TRAF3 in B lymphocytes leads to B-lymphoma development in miceC R Moore, Y Liu, C Shao, L R Covey, H C Morse, III and P Xie Leukemia 2012 26: 1122-1127; advance online publication, October 28, 2011; 10.1038/leu.2011.309 Full Text |  |  |  | Antigen receptor stereotypy across B-cell lymphoproliferations: the case of IGHV4-59/IGKV3-20 receptors with rheumatoid factor activityE Kostareli, M Gounari, A Janus, F Murray, X Brochet, V Giudicelli, S Pospisilova, D Oscier, L Foroni, P F di Celle, B Tichy, L B Pedersen, J Jurlander, M Ponzoni, A Kouvatsi, A Anagnostopoulos, K Thompson, N Darzentas, M-P Lefranc, C Belessi, R Rosenquist, F Davi, P Ghia and K Stamatopoulos Leukemia 2012 26: 1127-1131; advance online publication, November 4, 2011; 10.1038/leu.2011.311 Full Text |  |  |  | AML1/ETO and POU4F1 synergy drives B-lymphoid gene expression typical of t(8;21) acute myeloid leukemiaJ Dunne, D Mannari, T Farzaneh, A Gessner, F W van Delft, O Heidenreich, B D Young and D M Gascoyne Leukemia 2012 26: 1131-1135; advance online publication, November 8, 2011; 10.1038/leu.2011.316 Full Text |  |  |  | SF3B1 mutations in primary myelofibrosis: clinical, histopathology and genetic correlates among 155 patientsT L Lasho, C M Finke, C A Hanson, T Jimma, R A Knudson, R P Ketterling, A Pardanani and A Tefferi Leukemia 2012 26: 1135-1137; advance online publication, November 8, 2011; 10.1038/leu.2011.320 Full Text |  |  |  | SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implicationsF Damm, F Thol, O Kosmider, S Kade, P Löffeld, F Dreyfus, A Stamatoullas-Bastard, A Tanguy-Schmidt, O Beyne-Rauzy, S de Botton, A Guerci-Bresler, G Göhring, B Schlegelberger, A Ganser, O A Bernard, M Fontenay and M Heuser Leukemia 2012 26: 1137-1140; advance online publication, November 8, 2011; 10.1038/leu.2011.321 Full Text |  |  |  | Blockade of JAK2-mediated extrinsic survival signals restores sensitivity of CML cells to ABL inhibitorsE Traer, R MacKenzie, J Snead, A Agarwal, A M Eiring, T O'Hare, B J Druker and M W Deininger Leukemia 2012 26: 1140-1143; advance online publication, November 18, 2011; 10.1038/leu.2011.325 Full Text |  |  |  | Oral high-dose glucocorticoids and Ofatumumab in fludarabine-resistant Chronic Lymphocytic LeukemiaD E Spaner Leukemia 2012 26: 1144-1145; advance online publication, November 8, 2011; 10.1038/leu.2011.329 Full Text |  |  |  | Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosisO Meynet, M Bénéteau, M A Jacquin, L A Pradelli, A Cornille, M Carles and J-E Ricci Leukemia 2012 26: 1145-1147; advance online publication, November 11, 2011; 10.1038/leu.2011.327 Full Text |  |  |  | Do current response criteria in classical Ph-negative myeloproliferative neoplasms capture benefit for patients?G Barosi, A Tefferi and T Barbui on behalf of the ad hoc committee ‘Definition of clinically relevant outcomes for contemporarily clinical trials in Ph-neg MPNs’ Leukemia 2012 26: 1148-1149; advance online publication, November 22, 2011; 10.1038/leu.2011.337 Full Text |  |  |  | Expansion of NK cells from cord blood with antileukemic activity using GMP-compliant substances without feeder cellsJ Tanaka, J Sugita, S Shiratori, A Shigematu, S Asanuma, K Fujimoto, M Nishio, T Kondo and M Imamura Leukemia 2012 26: 1149-1152; advance online publication, December 6, 2011; 10.1038/leu.2011.345 Full Text |  | Corrigendum | Top |  | Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, G Morgan, P G Richardson, J Crowley, J Haessler, J Feather, A Hoering, P Moreau, X LeLeu, C Hulin, S K Klein, P Sonneveld, D Siegel, J Bladeé, H Goldschmidt, S Jagannath, J S Miguel, R Orlowski, A Palumbo, O Sezer and S V Rajkumar BGM Durie on behalf of the International Myeloma Working Group Leukemia 2012 26: 1153; 10.1038/leu.2012.15 Full Text |  |  |  | Bone morphogenetic proteins induce apoptosis in multiple myeloma cells by Smad-dependent repression of MYCT Holien, T K Våtsveen, H Hella, C Rampa, G Brede, L A G Grøseth, M Rekvig, M Børset, T Standal, A Waage and A Sundan Leukemia 2012 26: 1154; 10.1038/leu.2012.64 Full Text |  |  |  |  |  | Advertisement |  | |  | |  |  |  |  |  |  |  | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com |  |  |  |  |  |
|  | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2012 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved. |  | |
|
No comments:
Post a Comment